广告
加载中

香港砸几十亿投资多家内地独角兽 为其港股IPO铺好“红毯”

吴梅梅 2026-06-09 11:18
吴梅梅 2026/06/09 11:18

邦小白快读

EN
全文速览

本文核心内容是香港特区政府通过全资平台港投公司,出资几十亿投资内地硬科技独角兽,为这些企业赴港IPO铺路,重构香港资本市场估值体系的行业事件。

1. 当前投资进展:港投公司620亿港元起始资金已分配完毕,累计投资超过190个项目,已有10家企业在港上市,超20家筹备2026年登陆港股,近两年直接投资的10家内地独角兽都是港股IPO预备队,涵盖AI大模型、AI制药、工业AI、芯片、机器人等多个硬科技赛道。

2. 投资特征与收益:港投投资不同于普通财务投资,聚焦三大硬科技赛道,偏好增长成熟期项目,能达到1港元撬动8港元市场资金的放大效应,已完成上市的英矽智能项目,一年账面回报率达到112%,这件事的战略价值远高于单个项目的财务回报。

本文披露了香港资本市场对接内地硬科技品牌的最新动向,能为布局资本化、国际化的硬科技品牌提供重要参考。

1. 产业与资本趋势:当前硬科技、生命科技、新能源与绿色科技是香港资本和资本市场重点布局的赛道,香港正在重构这类未来产业的估值体系,符合赛道的品牌有机会获得更高的资本估值与更广阔的融资空间。

2. 资本化路径机会:港投公司专门投资有成熟产品、收入基础,准备冲刺IPO的增长成熟期硬科技企业,不仅能提供资本支持,还能凭借政府信用为品牌背书,撬动更多社会资本,对接港股IPO通道,符合条件的品牌可以抓住这一窗口期加速资本化进程。

3. 参考案例:文中的英矽智能、思谋科技等不同细分赛道的品牌,已经通过这一路径冲刺或完成上市,为同类品牌的资本化路径提供了可参考的样本。

本文披露了香港资本市场面向内地硬科技企业的最新政策动向,能给计划对接资本、冲刺IPO的科技类企业提供清晰的机会与风险参考。

1. 机会提示:香港政府通过港投公司布局,大力吸引内地硬科技企业赴港IPO,给处于增长成熟期、已经有成熟产品和收入的硬科技企业提供了清晰的上市通道,符合赛道要求的企业可以提前对接,借助政策红利完成上市融资。

2. 风险提示:赴港IPO仍存在多重不确定性,文中PPIO派欧云就因股权转让对价及所得税合规问题,IPO进程受阻;思谋科技等未盈利硬科技企业也存在无法通过港交所聆讯的变数,企业需要提前做好合规梳理与财务准备。

3. 可借鉴经验:企业可以借助港投的政府信用背书,撬动更多市场资金跟投,解决上市前的融资难题,提升自身IPO的成功率。

本文呈现了当前国内硬科技产业的资本风向,能为传统工厂转型智能化、对接资本市场提供重要启示与机会参考。

1. 产品研发方向指引:当前资本和香港资本市场都将硬科技、工业AI、机器人、芯片、新能源、AI制药等作为核心布局方向,传统工厂推进转型升级时,可以往这些符合资本偏好的方向布局,更容易获得资本支持对接上市。

2. 明确的商业机会:港投公司专门布局已经有成熟产品、稳定客户和收入,处于IPO准备阶段的增长成熟期企业,符合条件的硬科技制造工厂可以主动对接港投,获得资本助推和上市通道,解决上市前的融资与背书问题,加速企业发展。

3. 转型启示:工厂推进数字化、智能化升级符合当前产业发展的大趋势,只要落地成熟产品实现商业化,就能获得资本和资本市场的支持,转型成长的空间十分广阔。

本文梳理了港投公司投资内地硬科技推进港股IPO的整体布局,为面向科技企业和资本市场的各类服务商指明了行业发展方向和机会。

1. 行业发展趋势:香港正在打造面向硬科技的资本市场新生态,港投作为政府投资平台会持续引入大量内地硬科技企业赴港IPO,将带动投行保荐、尽调咨询、法律服务、融资服务等一系列相关服务需求的持续增长,行业红利明显。

2. 核心客户痛点:当前大量内地增长成熟期硬科技企业,已经有成熟产品和收入,但缺乏后期大额资本助推,也缺乏上市所需的信用背书,IPO过程中还面临合规、估值、募资等多方面问题,存在明确的服务需求。

3. 服务机会:服务商可以依托港投的投资信号,对接被投的IPO预备企业,针对性提供保荐、合规梳理、融资对接等相关服务,抓住这波硬科技企业赴港上市的行业红利。

本文介绍了港投公司服务港股平台招商引智的投资模式,对各类面向科创企业的投资、上市平台运营发展有较高的参考价值。

1. 市场需求梳理:当前内地大量增长成熟期硬科技企业,有明确的上市融资需求,同时也需要权威信用背书撬动社会资本,香港依托自身对接国际资本的优势,刚好能够匹配这类企业的需求,是平台发展的新增长点。

2. 可借鉴的运营模式:港投采取聚焦三大硬科技赛道,重点布局增长成熟期项目,以政府资本撬动八倍社会资本,再引导企业赴港上市的模式,既可以源源不断培育优质上市资源,又能逐步完善平台自身的产业生态,重构平台的估值体系,提升长期竞争力。

3. 风险规避提示:平台发展不需要过度纠结单个项目的短期盈亏,要着眼整体生态的战略价值,同时需要提前把控拟上市企业的财务合规、盈利预期等风险,保障平台的长期稳定发展。

本文披露了香港港投公司投资培育内地硬科技赴港IPO的全新实践,是香港重构资本市场生态的重大实验,为产业研究提供了丰富的新素材。

1. 产业新动向:当前香港依托自身国际金融中心优势,通过政府全资投资平台定向投资内地优质硬科技企业,引导企业赴港上市,推动香港资本市场从传统地产、金融为主,转向以AI、生物医药、新能源等未来产业为主重构估值锚点,这是国内区域资本市场竞争的全新动向。

2. 创新商业模式:这种“政策+市场”双轮驱动的模式,不同于传统PE/VC的财务投资逻辑,也不同于内地政府基金偏好投早投小的策略,港投聚焦三大赛道,偏好增长成熟期项目,实现1港元撬动8港元社会资本的杠杆效应,兼顾财务回报和战略目标,模式创新值得深入研究。

3. 研究方向启示:这种模式后续能否持续推动香港资本市场生态转型,未盈利硬科技企业上市后的长期表现如何,都值得后续跟踪研究,也为各地政府通过产业资本引导产业发展提供了重要的研究样本。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article covers a major industry development: the Government of the Hong Kong Special Administrative Region is investing billions via its fully-owned platform, Hong Kong Investment Corporation (HKIC), to back mainland China's hard tech unicorns, paving the way for their IPOs in Hong Kong and restructuring the valuation system of Hong Kong's capital market.

1. Current investment progress: HKIC has fully allocated its initial capital of HK$62 billion, with cumulative investments in over 190 projects. Ten portfolio companies have already listed in Hong Kong, and more than 20 are preparing for IPOs by 2026. All 10 mainland unicorns HKIC has directly invested in over the past two years are in the pipeline for Hong Kong IPOs, spanning major hard tech sectors including large AI models, AI drug discovery, industrial AI, chips, and robotics.

2. Investment characteristics and returns: Unlike pure financial investment, HKIC's strategy focuses on three core hard tech sectors and prioritizes growth-stage mature projects. It delivers a leverage effect where every HK$1 of its capital mobilizes HK$8 in private market capital. For example, its listed portfolio company Insilico Medicine delivered a 112% book return in one year, and the overall strategic value of this initiative far outweighs the financial returns of individual projects.

This article reveals the latest development of Hong Kong's capital market in connecting with mainland Chinese hard tech brands, offering key insights for hard tech brands planning to pursue capitalization and international expansion.

1. Industry and capital trends: Hard tech, life science, new energy and green tech are now the core focus of Hong Kong's capital and capital market. Hong Kong is rebuilding the valuation system for these future-oriented industries, and brands aligned with these sectors can access higher capital valuations and broader financing opportunities.

2. Capitalization pathway opportunities: HKIC specifically invests in growth-stage mature hard tech companies with established products and revenue bases that are preparing for IPOs. It not only provides capital support but also offers official credit endorsement to leverage more social capital and connect companies to Hong Kong's IPO pipeline. Eligible brands can seize this window to accelerate their capitalization process.

3. Reference cases: Brands across different sub-sectors covered in the article, such as Insilico Medicine and SmartMore, have either completed or are pursuing listing via this pathway, providing a replicable reference for peer brands planning capitalization.

This article discloses the latest policy developments in Hong Kong's capital market for mainland Chinese hard tech companies, offering clear insights into opportunities and risks for tech firms planning to access capital and pursue IPOs.

1. Opportunity note: The Hong Kong government, through HKIC, is actively attracting mainland Chinese hard tech companies to list in Hong Kong, creating a clear listing pathway for growth-stage mature hard tech firms with established products and revenue. Companies that fit the sector criteria can proactively engage with the platform to complete IPO financing by leveraging this policy dividend.

2. Risk note: There are still multiple uncertainties in pursuing a Hong Kong IPO. The article notes that PPIO Cloud's IPO process stalled over issues related to transfer pricing and income tax compliance, while unprofitable hard tech firms like SmartMore still face uncertainty around passing the HKEX hearing. Companies should complete compliance reviews and financial preparations in advance.

3. Key takeaways: Companies can leverage HKIC's official credit endorsement to attract more follow-on investment from market participants, solve pre-IPO financing challenges, and improve their chances of a successful IPO.

This article outlines the current capital trends in China's hard tech industry, offering key insights and opportunity references for traditional factories pursuing intelligent transformation and access to capital markets.

1. R&D direction guidance: Capital and Hong Kong's capital market now prioritize hard tech, industrial AI, robotics, chips, new energy, and AI drug discovery as core investment areas. When pursuing transformation and upgrading, traditional factories can align their development with these capital-preferred sectors to easier access capital support and pursue listing.

2. Clear business opportunities: HKIC specifically targets growth-stage mature companies with established products, stable customers and revenue that are preparing for IPO. Eligible hard tech manufacturing factories can proactively engage with HKIC to obtain capital backing and access to the listing pipeline, solving pre-IPO financing and endorsement needs to accelerate corporate growth.

3. Transformation insights: Digital and intelligent upgrading for factories aligns with the broader trend of industrial development. Once factories develop mature commercialized products, they can access support from capital and capital markets, opening up broad space for transformation and growth.

This article maps out HKIC's overall layout of investing in mainland Chinese hard tech companies to advance their Hong Kong IPOs, pointing out industry development directions and opportunities for various service providers serving tech companies and capital markets.

1. Industry trend: Hong Kong is building a new capital market ecosystem focused on hard tech. As a government-owned investment platform, HKIC will continue to bring a large volume of mainland Chinese hard tech companies to list in Hong Kong, driving sustained growth in demand for a full range of related services including investment banking sponsorship, due diligence consulting, legal services, and financing services, creating significant industry dividend.

2. Core client pain points: A large number of growth-stage mature mainland Chinese hard tech companies already have established products and revenue, but lack access to large-scale late-stage capital, lack official credit endorsement required for listing, and face multiple challenges around compliance, valuation, and fundraising during the IPO process, creating clear unmet service demand.

3. Service opportunities: Service providers can use HKIC's investment signal to identify portfolio companies in the IPO pipeline, and offer targeted services including sponsorship, compliance review, and financing connection to capture the industry dividend from this wave of hard tech IPOs in Hong Kong.

This article introduces HKIC's investment model for attracting high-quality tech companies to the Hong Kong stock platform, offering valuable reference for the operation and development of all types of investment and listing platforms serving tech startups.

1. Market demand mapping: A large number of growth-stage mature mainland Chinese hard tech companies have clear demand for IPO financing, and also need authoritative credit endorsement to mobilize social capital. Leveraging its unique advantage in connecting to international capital, Hong Kong is well-positioned to meet these demands, creating a new growth driver for platforms.

2. Replicable operation model: HKIC's model focuses on three core hard tech sectors, prioritizes growth-stage mature projects, uses government capital to mobilize 8x social capital, and then guides companies to list in Hong Kong. This model continuously cultivates high-quality listing resources, gradually improves the platform's own industrial ecosystem, restructures the platform's valuation system, and enhances long-term competitiveness.

3. Risk mitigation guidance: Platforms do not need to overemphasize short-term profits from individual projects, and should instead focus on the strategic value of the overall ecosystem. At the same time, they should proactively manage risks including financial compliance and earnings expectations for pre-IPO companies to ensure long-term stable development of the platform.

This article presents the new practice of HKIC investing in and cultivating mainland Chinese hard tech companies for Hong Kong IPOs, a major experiment in restructuring Hong Kong's capital market ecosystem that provides rich new materials for industrial research.

1. New industry trend: Leveraging its advantage as an international financial center, Hong Kong is using a fully government-owned investment platform to make targeted investments in high-quality mainland Chinese hard tech companies and guide them to list in Hong Kong. This is pushing Hong Kong's capital market to shift its valuation anchor from traditional sectors including real estate and finance to future-oriented industries including AI, biomedicine and new energy, representing a completely new development in regional capital market competition in China.

2. Innovative business model: This "policy + market" dual-driven model differs from the pure financial investment logic of traditional PE/VC, and also differs from the early-stage, small-project preference of mainland Chinese government funds. HKIC focuses on three core sectors and prioritizes growth-stage mature projects, delivering a leverage effect of HK$1 in government capital mobilizing HK$8 in social capital, balancing financial returns and strategic goals. This model innovation merits in-depth research.

3. Research agenda implications: Whether this model can sustainably drive the transformation of Hong Kong's capital market ecosystem, and how unprofitable hard tech companies will perform in the long term after listing, are both worthy of continued follow-up research. This initiative also provides an important research sample for regional governments seeking to guide industrial development via industrial capital.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

作者 | 吴梅梅

来源 |IT桔子

2026年5月,上海大模型独角兽阶跃星辰的办公室里,一份近25亿美元的融资协议刚刚落笔。投资方名单里,除了老股东腾讯、五源资本,还出现了一个此前在创投圈并不高调的名字——香港投资管理有限公司(简称:港投公司)。

而港投公司押注的,不仅是一家大模型公司,更是一个强烈的信号——中国香港特区政府正在用真金白银,为中国大陆硬科技企业的IPO之路铺下最后一里红毯。

但这只是冰山一角。

根据香港特区政府财政司司长陈茂波在2026年2月发表的《财政预算案》披露,港投公司全面营运至今累计投资已超过190个项目(含直接或间接投资),其中10家企业已在香港上市,另有超过20家正筹备在今年登陆港股。

截至2026年5月,港投公司的620亿港元起始资金已大致分配完毕,香港特区政府已明确将“适时注资”。

它超越了单纯的财务投资,是一场以投资为支点,为香港资本市场“育苗”,重构估值锚点的宏大实验。

两年投10家内地公司,

都是港股IPO“预备队”

根据IT桔子数据来看,港投公司近两年的直接对外投资至少覆盖了10家内地明星公司,它们构成了一个清晰的上市梯队。

港股公司近两年在国内的直接投资案例(部分)

其中,已经明确在港交所IPO的是AI制药公司英矽智能。

在拟IPO这一梯队中,目前,站在上市起跑线最前端的是思谋科技。

思谋科技成立于2019年底,创始人是香港中文大学计算机科学工程系教授,原腾讯杰出科学家、优图实验室X-Lab负责人贾佳亚博士。2024年6月获得港投公司参与的C轮融资1.28亿美元,投后估值12.3亿美元,已位列独角兽行列。

2026年3月16日,思谋科技正式向港交所递交招股书,摩根士丹利、中金公司、德意志银行联席保荐,冲刺“全球工业AI智能体第一股”。招股书显示,其2025年收入已达10.86亿元,同比增长44%,但净亏损也扩大至9.91亿元。

紧随其后的是百图生科。

这家由百度创始人李彦宏牵头创立的生命科学垂类大模型独角兽公司,在2024年6月获得港投公司战略投资后,于2026年3月被曝以保密形式向港交所递交上市申请,中金公司、摩根士丹利和瑞银协助筹备。

而在通用AI大模型赛道,港投公司押注了阶跃星辰。一个值得关注的信号是阶跃星辰在今年4月刚刚完成股改、拆除红筹架构的动作,被市场普遍视为赴港IPO的前置步骤。

另有一家港投的被投项目——云计算服务商PPIO派欧云,在2025年6月,也就是港投投资仅一个月后,它就提交了赴港上市申请,由工银国际、申万宏源为担任联席保荐人。

值得一提的是,PPIO派欧云创始人是一位曾经的明星创业者,也就是曾创办PPTV的姚欣。

不过,至今一年过去了,其IPO进程受阻,原因或是监管要求——证监会曾在去年10月对派欧云IPO作出关于股权转让对价及所得税等合规情况的问询,要求补充材料。

此外,港投公司还投资了康诺思腾(手术机器人,D轮)、银河通用机器人(具身智能,天使+轮)、赛昉科技(RISC-V芯片,战略投资)、逸动科技(船用电动化,D轮,创始人是香港科技大学毕业生,师从李泽湘教授)等中国内地企业,这些都可能成为港股IPO“预备队”。

在2025年12月,曾有媒体爆料出具身智能独角兽银河通用机器人已在进行上市辅导,拟2026Q1最快递表港交所,虽然该消息的结果被证实为不属实,但其上市预期已引发市场高度关注。

投资回报怎么算?

英矽智能是可查样本

要评估港投公司在内地的投资绩效,英矽智能是目前唯一可供完整复盘的全周期样本。

从投资时点看,港投公司于2025年6月参与AI制药独角兽公司“英矽智能”E轮融资,该轮融资总额1.23亿美元,投后估值13.31亿美元。

仅仅半年后,英矽智能于2025年12月30日登陆港交所,IPO募资总额22.77亿港元,发行价24.05港元。上市首日,开盘价35港元,收盘价29.98港元,涨幅24.66%。

英矽智能在近几个月来连续宣布与施维雅、礼来、衡泰生物、齐鲁制药达成4笔交易大单,BD总金额累计超10亿美元,其自主研发的核心AI平台Pharma.AI覆盖抗肿瘤、中枢神经系统、心血管与代谢类疾病三大核心治疗领域,将全面进入商业化验证阶段。

截至2026年6月4日上午,其股价稳于38.58港元,总市值达到220.8亿港元,约28.17亿美元。

若按E轮估值13.31亿美元与当下市值对比,港投公司这笔投资仅一年,就达到了账面回报率约为112%。即便考虑上市后股份稀释,其浮盈年化率也应在100%以上。

8倍资本放大效应,

战略意义更显著

港投公司的投资策略,不能简单用PE或VC的逻辑来理解,其谋划远超一般财务投资。

作为香港特区政府全资拥有的投资平台,它肩负着双重使命:追求中长期合理财务回报,同时通过支持香港创科和策略性产业发展,提升香港长远的竞争力。

这种“政策+市场”的双轮驱动,决定了其投资行为的三个鲜明特征。

第一是赛道聚焦的极致化。

港投公司将资金高度集中于硬科技、生命科技、新能源与绿色科技三大领域,这与香港交易所近年来力推的18C章(特专科技公司上市规则)形成完美呼应。

它通过一级市场投资把企业养大,再引导它们赴港上市,最终反哺香港的国际金融中心地位。

第二是投资阶段的“后发先至”。

与许多中国内地政府基金偏好“投早、投小”不同,据港投公司年报显示,其投资阶段偏好增长期(占69%)和成熟期(占21%)项目,这意味着它并非在赌早期的“技术彩票”,而是在企业商业化爆发的前夜精准下注。

这种策略降低了技术失败的风险,却也要求投资者具备极强的产业判断力——要在合适的时机进入那些已有成熟产品、头部客户和收入,但缺乏后期资本助推和上市通道的企业。

第三是资本杠杆的放大效应。

港投公司行政总裁陈家齐曾透露,其每投入1港元,已撬动超过8港元的市场长期资金跟投。

这本质上是一种“信号投资”——当政府资本以直投或跟投方式进入思谋科技、百图生科、阶跃星辰时,它向国际主权基金、退休基金、家族办公室传递了一个强烈信号:这些企业可能已经通过了港投公司的尽调,并符合香港的上市标准与长期发展潜力。

这种稀缺的政府信用杠杆,在当前的IPO难题中显得尤为珍贵。

不过,港投公司的投资棋局,下一步将面临真正的考验。

思谋科技虽已递表,但其2025年净亏损9.91亿元的财务数据,能否通过港交所聆讯仍存变数;百图生科的AI制药商业化路径也尚处早期。

然而,对于港投公司而言,单项目的短期盈亏或许并非最终标尺。

当港投公司把思谋科技、百图生科等一批硬科技企业推向港股,它实际上是在为香港资本市场重构估值锚点——从传统的地产、金融,转向AI、机器人、生物医药等未来产业。

这种投资生态级别的转变,远比单一项目的财务回报更具战略价值。

注:文/吴梅梅,文章来源:IT桔子(公众号ID:itjuzi521),本文为作者独立观点,不代表亿邦动力立场。

文章来源:IT桔子

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0